These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors. Neagu MR; Reardon DA Curr Treat Options Oncol; 2015 Nov; 16(11):54. PubMed ID: 26454859 [TBL] [Abstract][Full Text] [Related]
25. HOXC6/8/10/13 predict poor prognosis and associate with immune infiltrations in glioblastoma. Yu M; Yu S; Zhou W; Yi B; Liu Y Int Immunopharmacol; 2021 Dec; 101(Pt A):108293. PubMed ID: 34763232 [TBL] [Abstract][Full Text] [Related]
26. Extrinsic factors associated with the response to immunotherapy in glioblastoma. Bi H; Zhang C Cancer Lett; 2021 Jul; 511():47-55. PubMed ID: 33933551 [TBL] [Abstract][Full Text] [Related]
27. Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma. Yeo AT; Charest A J Cell Biochem; 2017 Sep; 118(9):2516-2527. PubMed ID: 28230277 [TBL] [Abstract][Full Text] [Related]
28. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV Trials; 2018 May; 19(1):293. PubMed ID: 29801515 [TBL] [Abstract][Full Text] [Related]
29. Current challenges in designing GBM trials for immunotherapy. Weathers SP; Gilbert MR J Neurooncol; 2015 Jul; 123(3):331-7. PubMed ID: 25577401 [TBL] [Abstract][Full Text] [Related]
30. Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma. Li Y; Ma Y; Wu Z; Xie R; Zeng F; Cai H; Lui S; Song B; Chen L; Wu M Front Immunol; 2021; 12():790674. PubMed ID: 34899760 [TBL] [Abstract][Full Text] [Related]
31. Novel Immunotherapeutics for Treatment of Glioblastoma: The Last Decade of Research. Khansur E; Shah AH; Lacy K; Komotar RJ Cancer Invest; 2019; 37(1):1-7. PubMed ID: 30632816 [TBL] [Abstract][Full Text] [Related]
32. Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme. Zhang B; Shen R; Cheng S; Feng L Cancer Med; 2019 Jun; 8(6):2897-2907. PubMed ID: 31038851 [TBL] [Abstract][Full Text] [Related]
33. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Preusser M; Lim M; Hafler DA; Reardon DA; Sampson JH Nat Rev Neurol; 2015 Sep; 11(9):504-14. PubMed ID: 26260659 [TBL] [Abstract][Full Text] [Related]
34. Immunotherapy for Neuro-oncology. Majd NK; Dasgupta PR; de Groot JF Adv Exp Med Biol; 2021; 1342():233-258. PubMed ID: 34972967 [TBL] [Abstract][Full Text] [Related]
35. Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme. Ung N; Yang I J Neurooncol; 2015 Jul; 123(3):473-81. PubMed ID: 26070553 [TBL] [Abstract][Full Text] [Related]